These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

663 related items for PubMed ID: 22431920

  • 1. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
    Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pèlegrin A.
    Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
    [Abstract] [Full Text] [Related]

  • 2. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts.
    Larbouret C, Robert B, Bascoul-Mollevi C, Penault-Llorca F, Ho-Pun-Cheung A, Morisseau S, Navarro-Teulon I, Mach JP, Pèlegrin A, Azria D.
    Ann Oncol; 2010 Jan; 21(1):98-103. PubMed ID: 19889608
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.
    Gaborit N, Larbouret C, Vallaghe J, Peyrusson F, Bascoul-Mollevi C, Crapez E, Azria D, Chardès T, Poul MA, Mathis G, Bazin H, Pèlegrin A.
    J Biol Chem; 2011 Apr 01; 286(13):11337-45. PubMed ID: 21282108
    [Abstract] [Full Text] [Related]

  • 5. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
    Lindberg JM, Newhook TE, Adair SJ, Walters DM, Kim AJ, Stelow EB, Parsons JT, Bauer TW.
    Neoplasia; 2014 Jul 01; 16(7):562-71. PubMed ID: 25117978
    [Abstract] [Full Text] [Related]

  • 6. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
    Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL.
    Cancer Biol Ther; 2011 Sep 01; 12(5):436-46. PubMed ID: 21725209
    [Abstract] [Full Text] [Related]

  • 7. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
    Oude Munnink TH, de Vries EG, Vedelaar SR, Timmer-Bosscha H, Schröder CP, Brouwers AH, Lub-de Hooge MN.
    Mol Pharm; 2012 Nov 05; 9(11):2995-3002. PubMed ID: 23003202
    [Abstract] [Full Text] [Related]

  • 8. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
    Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ.
    Cancer Res; 2006 Feb 01; 66(3):1630-9. PubMed ID: 16452222
    [Abstract] [Full Text] [Related]

  • 9. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
    Larbouret C, Robert B, Navarro-Teulon I, Thèzenas S, Ladjemi MZ, Morisseau S, Campigna E, Bibeau F, Mach JP, Pèlegrin A, Azria D.
    Clin Cancer Res; 2007 Jun 01; 13(11):3356-62. PubMed ID: 17545543
    [Abstract] [Full Text] [Related]

  • 10. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
    Kimple RJ, Vaseva AV, Cox AD, Baerman KM, Calvo BF, Tepper JE, Shields JM, Sartor CI.
    Clin Cancer Res; 2010 Feb 01; 16(3):912-23. PubMed ID: 20103665
    [Abstract] [Full Text] [Related]

  • 11. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.
    Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS.
    Clin Cancer Res; 2008 Aug 15; 14(16):5142-9. PubMed ID: 18698032
    [Abstract] [Full Text] [Related]

  • 12. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M, Yamashita Y, Kubo N, Yashiro M, Ohira M, Ako E, Tanaka H, Muguruma K, Sawada T, Hirakawa K.
    Oncol Rep; 2012 Jul 15; 28(1):49-54. PubMed ID: 22562413
    [Abstract] [Full Text] [Related]

  • 13. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
    Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL.
    Cancer Res; 2013 Oct 01; 73(19):6013-23. PubMed ID: 23918797
    [Abstract] [Full Text] [Related]

  • 14. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS.
    Clin Cancer Res; 2010 Mar 01; 16(5):1509-19. PubMed ID: 20179222
    [Abstract] [Full Text] [Related]

  • 15. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV.
    Clin Cancer Res; 2009 May 15; 15(10):3484-94. PubMed ID: 19447865
    [Abstract] [Full Text] [Related]

  • 16. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.
    Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, Park J, Lee JH, Oh DY, Im SA, Bang YJ, Kim TY.
    PLoS One; 2009 Jun 16; 4(6):e5933. PubMed ID: 19529774
    [Abstract] [Full Text] [Related]

  • 17. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM, Sassi F, Catalano I, Torri V, Migliardi G, Zanella ER, Throsby M, Bertotti A, Trusolino L.
    Clin Cancer Res; 2015 Dec 15; 21(24):5519-31. PubMed ID: 26296355
    [Abstract] [Full Text] [Related]

  • 18. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
    García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M.
    Clin Cancer Res; 2012 May 01; 18(9):2603-12. PubMed ID: 22407832
    [Abstract] [Full Text] [Related]

  • 19. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
    Groeneweg JW, Hernandez SF, Byron VF, DiGloria CM, Lopez H, Scialabba V, Kim M, Zhang L, Borger DR, Tambouret R, Foster R, Rueda BR, Growdon WB.
    Clin Cancer Res; 2014 Dec 15; 20(24):6517-6528. PubMed ID: 25294905
    [Abstract] [Full Text] [Related]

  • 20. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
    Metro G, Finocchiaro G, Toschi L, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L, Cappuzzo F.
    Rev Recent Clin Trials; 2006 Jan 15; 1(1):1-13. PubMed ID: 18393776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.